Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly

Benzinga

07 Feb 2023

Bristol-Myers Squibb & Co (NYSE: BMY) has returned the exclusive rights to Dragonfly Therapeutics' IL-12 oncology candidate.
In 2020, BMS handed out $475 million in near-term and upfront payments deal to license the interleukin-12 (IL-12) immunotherapy program, dubbed DF6002.
The therapy is currently being assessed in a phase 1/2 trial in patients with various solid tumors as a monotherapy and combination with BMS' cancer blockbuster Opdivo (Nivolumab).
According to the press release, BMS is still conducting clinical development for DF6002, but Dragonfly is set to take over in the coming weeks.
Dragonfly now holds all the rights for the IL12 cytokine—the most advanced drug in Dragonfly's cytokine pipeline.
Last month, Bristol-Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate with Dragonfly Therapeutics.
The announcement marks the first TriNKET opt-in outside of oncology.
Dragonfly will receive a $25 million payment and is eligible for potential future milestones and royalties on net sales.
Price Action: BMY shares are down 0.18% at $74.32 on the last check Monday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2309144293"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2309144293\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2309144293?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/whZOZUxwYGUfMx_S4MwEUQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/00752f47b6d9302c837ff0a0a67b82d3","is_english":true,"pubTime":"2023-02-07 01:41","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2309144293","market":"us","top_or_hot":-1,"title":"Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly","media":"Benzinga","content":"<html><body><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/t_72852E2HLObeNLK1rBZA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/00752f47b6d9302c837ff0a0a67b82d3\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>Bristol-Myers</strong> <strong>Squibb &amp; Co</strong> (NYSE: BMY) has returned the exclusive rights to <strong>Dragonfly Therapeutics</strong>' IL-12 oncology candidate.</li>\n<li>In 2020, BMS handed out $475 million in near-term and upfront payments deal to license the interleukin-12 (IL-12) immunotherapy program, dubbed DF6002. </li>\n<li>The therapy is currently being assessed in a phase 1/2 trial in patients with various solid tumors as a monotherapy and combination with BMS' cancer blockbuster Opdivo (Nivolumab).</li>\n<li>According to the press release, BMS is still conducting clinical development for DF6002, but Dragonfly is set to take over in the coming weeks.</li>\n<li>Dragonfly now holds all the rights for the IL12 cytokine—the most advanced drug in Dragonfly's cytokine pipeline. </li>\n<li>Last month, Bristol-Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate with Dragonfly Therapeutics.</li>\n<li>The announcement marks the first TriNKET opt-in outside of oncology.</li>\n<li>Dragonfly will receive a $25 million payment and is eligible for potential future milestones and royalties on net sales.</li>\n<li><strong>Price Action:</strong> BMY shares are down 0.18% at $74.32 on the last check Monday.</li>\n</ul>\n<p>Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.</p>\n<p>This article Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly originally appeared on Benzinga.com</p>.\n<p><i>© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBig Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-07 01:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/big-pharma-bristol-myers-returns-174114403.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol-Myers Squibb & Co (NYSE: BMY) has returned the exclusive rights to Dragonfly Therapeutics' IL-12 oncology candidate.\nIn 2020, BMS handed out $475 million in near-term and upfront payments deal...</p>\n\n<a href=\"https://finance.yahoo.com/news/big-pharma-bristol-myers-returns-174114403.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.yahoo.com/news/big-pharma-bristol-myers-returns-174114403.html","article_id":"2309144293","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/whZOZUxwYGUfMx_S4MwEUQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/00752f47b6d9302c837ff0a0a67b82d3"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2309144293","pubTimestamp":1675705274,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Bristol-Myers Squibb & Co (NYSE: BMY) has returned the exclusive rights to Dragonfly Therapeutics' I","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"大型制药公司百时美施贵宝将价值4.75亿美元的IL-12肿瘤学资产返还给蜻蜓","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":0.9,"IL":1,"MYE":1},"content_text":"Bristol-Myers Squibb & Co (NYSE: BMY) has returned the exclusive rights to Dragonfly Therapeutics' IL-12 oncology candidate.\nIn 2020, BMS handed out $475 million in near-term and upfront payments deal to license the interleukin-12 (IL-12) immunotherapy program, dubbed DF6002. \nThe therapy is currently being assessed in a phase 1/2 trial in patients with various solid tumors as a monotherapy and combination with BMS' cancer blockbuster Opdivo (Nivolumab).\nAccording to the press release, BMS is still conducting clinical development for DF6002, but Dragonfly is set to take over in the coming weeks.\nDragonfly now holds all the rights for the IL12 cytokine—the most advanced drug in Dragonfly's cytokine pipeline. \nLast month, Bristol-Myers Squibb exercised its option to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate with Dragonfly Therapeutics.\nThe announcement marks the first TriNKET opt-in outside of oncology.\nDragonfly will receive a $25 million payment and is eligible for potential future milestones and royalties on net sales.\nPrice Action: BMY shares are down 0.18% at $74.32 on the last check Monday.\n\nDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.\nThis article Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly originally appeared on Benzinga.com.\n© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}